S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:AXGN - AxoGen Stock Price, Forecast & News

$14.31
-0.71 (-4.73 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$14.18
Now: $14.31
$15.13
50-Day Range
$14.14
MA: $16.84
$18.60
52-Week Range
$10.91
Now: $14.31
$25.84
Volume352,800 shs
Average Volume345,275 shs
Market Capitalization$564.80 million
P/E RatioN/A
Dividend YieldN/A
Beta0.32
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$83.94 million
Book Value$3.84 per share

Profitability

Net Income$-22,400,000.00

Miscellaneous

EmployeesN/A
Market Cap$564.80 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.


Stock Trades Or Predictions (Ad)


Want to know which stocks should be on your radar this week? Every Sunday we send out the 3 Stock Trades that we predict will be big winners for the week ahead.

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc (NASDAQ:AXGN) posted its quarterly earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.04. The medical equipment provider earned $28.56 million during the quarter, compared to analyst estimates of $28.10 million. AxoGen had a negative return on equity of 17.82% and a negative net margin of 26.79%. View AxoGen's Earnings History.

When is AxoGen's next earnings date?

AxoGen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for AxoGen.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $106.6 million, compared to the consensus revenue estimate of $107.76 million.

What price target have analysts set for AXGN?

5 brokerages have issued 1-year price objectives for AxoGen's stock. Their forecasts range from $21.00 to $30.00. On average, they anticipate AxoGen's share price to reach $25.00 in the next year. This suggests a possible upside of 74.7% from the stock's current price. View Analyst Price Targets for AxoGen.

What is the consensus analysts' recommendation for AxoGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

What are Wall Street analysts saying about AxoGen stock?

Here are some recent quotes from research analysts about AxoGen stock:
  • 1. BTIG Research analysts commented, "Raise PT to $29 We reiterate our Buy rating and raise our price target to $29 (from $28) following 1Q19 results. 1Q19 results beat both BTIG and Consensus est. with rev. of $23.3M (+34.9% Y/Y) coming in ahead of (~29% implied). Expenses were elevated as one-timers, increasing sales reps, and costs associated with RECON stepped up, but mgmt. expects these costs to moderate through the year. When we upgraded AXGN intra-quarter (here), the crux of our thesis was that improved stability and hiring trends in the sales force following the leadership transition would lead to more consistent execution and allow AXGN to return to improved growth. Thus far, results are playing out as we surmised but we acknowledge it’s still early in the year." (5/10/2019)
  • 2. Cantor Fitzgerald analysts commented, "We think AXGN is one of the most compelling growth stories in medtech, with what we believe is sustainable top-line growth of north of 30% for the next two years. We expect utilization to accelerate as favorable clinical and economic data builds and increases surgeon awareness. We would also expect the company to continue to pursue additional market opportunities, as the technology is applicable to nerves across the body. Valuation Summary We value AXGN using a 6x EV/Sales multiple on our 2020 sales estimate to arrive at our 12-month price target of $26." (1/18/2019)

Has AxoGen been receiving favorable news coverage?

News articles about AXGN stock have trended very negative recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AxoGen earned a coverage optimism score of -3.6 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for AxoGen.

Are investors shorting AxoGen?

AxoGen saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 1,950,000 shares, an increase of 10.2% from the November 28th total of 1,770,000 shares. Based on an average trading volume of 364,600 shares, the short-interest ratio is currently 5.3 days. Currently, 5.5% of the company's stock are short sold. View AxoGen's Current Options Chain.

Who are some of AxoGen's key competitors?

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Exelixis (EXEL), Micron Technology (MU), Xilinx (XLNX), Advanced Micro Devices (AMD), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Amarin (AMRN) and NVIDIA (NVDA).

Who are AxoGen's key executives?

AxoGen's management team includes the folowing people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
  • Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
  • Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
  • Mr. Michael Donovan, VP of Operations (Age 54)
  • Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel.

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.43%) and Pennsylvania Trust Co (0.51%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Jamie Mark Grooms, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

Which major investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Pennsylvania Trust Co. Company insiders that have sold AxoGen company stock in the last year include David K Hansen and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $14.31.

How big of a company is AxoGen?

AxoGen has a market capitalization of $564.80 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. View Additional Information About AxoGen.

What is AxoGen's official website?

The official website for AxoGen is http://www.axogeninc.com/.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]


MarketBeat Community Rating for AxoGen (NASDAQ AXGN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  394 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  673
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel